CHA
VRTX icon

Carmichael Hill & Associates’s Vertex Pharmaceuticals VRTX Stock Holding History

Carmichael Hill & Associates’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Hold
0
– -$40.7K – 821
2023
Q4 		– Hold
0
– – – 381
2023
Q3 		– Hold
0
– – – 386
2023
Q2 		– Hold
0
– – – 390
2023
Q1 		– Hold
0
– – – 392
2022
Q4 		– Hold
0
– – – 414
2022
Q3 		– Hold
0
– – – 416
2022
Q2 		– Sell
-100
Closed -$26.8K – 421
2022
Q1 		$26K Buy
+100
New +$23.7K 0.01% 464

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Carmichael Hill & Associates's VRTX Position: Q3 2024 in Review

Carmichael Hill & Associates held its Vertex Pharmaceuticals (VRTX) position steady in Q3 2024 at 18 shares worth $8.37K. The position accounts for ﹤0.01% of the portfolio, ranked #608.

Carmichael Hill & Associates first reported a position in VRTX in Q4 2020 and has held it in 16 quarters since. The position peaked at $8.44K in Q2 2024. 1,544 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Carmichael Hill & Associates held 18 shares of Vertex Pharmaceuticals worth $8.37K as of Q3 2024.
  • Carmichael Hill & Associates left its Vertex Pharmaceuticals share count unchanged in Q3 2024.
  • Vertex Pharmaceuticals made up ﹤0.01% of Carmichael Hill & Associates's portfolio in Q3 2024, its #608 holding.
  • Carmichael Hill & Associates first reported a position in Vertex Pharmaceuticals in Q4 2020 and has held it in 16 quarters since.
  • Carmichael Hill & Associates's Vertex Pharmaceuticals position peaked at $8.44K in Q2 2024.
  • 1,544 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Carmichael Hill & Associates's 13F filing for Q3 2024, filed 29 Oct 2024.